Autonomix achieves design lock for RF Ablation Catheter

Autonomix (AMIX) Medical announced the milestone achievement of design lock for its radio frequency ablation catheter specifically designed to ablate nerves transvascularly in targeted areas following the successful completion of animal testing. “There continues to be a much-needed shift in the treatment paradigm for pancreatic cancer patients offering a reduction of pain and improvement in quality of life. Our technology has continued to demonstrate the potential to address this urgent need, and these continued technical achievements enable us to support a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the United States as a treatment for pancreatic cancer pain,” commented Brad Hauser, CEO of Autonomix. “This design lock represents a meaningful milestone in the advancement of our technology development, placing us another step closer to commencing a pivotal clinical trial, planned in the second half of 2025, and beyond to potential De Novo clearance.”